Walleye Capital
VERA icon

Walleye Capital’s Vera Therapeutics VERA Stock Holding History

Walleye Capital’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100
Closed -$2.91K – 5176
2025
Q3 		$2.91K Sell
100
-600
-86% -$13.9K ﹤0.01% 4342
2025
Q2 		$16.5K Buy
+700
New +$15.7K ﹤0.01% 4260

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Walleye Capital's VERA Position: Q2 2026 in Review

Walleye Capital sold out of Vera Therapeutics (VERA) in Q2 2026, closing a stake of 23,156 shares — an estimated $932K sold.

Walleye Capital first reported a position in VERA in Q4 2022 and held it in 7 quarters. The position peaked at $4.77M in Q1 2025. 220 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • Walleye Capital reported no remaining Vera Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Walleye Capital sold 23,156 Vera Therapeutics shares in Q2 2026, an estimated $932K.
  • Walleye Capital first reported a position in Vera Therapeutics in Q4 2022 and held it in 7 quarters.
  • Walleye Capital's Vera Therapeutics position peaked at $4.77M in Q1 2025.
  • 220 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.